Skip to main content
Fig. 1 | BMC Rheumatology

Fig. 1

From: Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis

Fig. 1

Lanraplenib inhibits human B-cell survival, activation, maturation, and antibody production of in vitro. a-b Lanraplenib-treated B cells from healthy donors (HD) were stimulated with recombinant B-cell activating factor (BAFF) (250 ng/mL) for 48 h. Survival was measured by RealTime Glo. Comparison of unstimulated and BAFF-stimulated B cells with and without lanraplenib treatment are shown in a. Survival of untreated cells without BAFF stimulation was subtracted from all wells to generate dose response curve in b. EC50: 130 nM; n = 6. c Lanraplenib-treated B cells isolated from blood of HD or individuals with SLE were stimulated with F (ab’)2 anti-IgM antibody (20 μg/mL) for 16 h. Activation was measured by the expression of CD69. EC50: 298 nM (HD), 340 nM (SLE); n = 3 donors per group. d Lanraplenib-treated naïve B cells (CD27−) from HD were stimulated with a cocktail of interleukin (IL)-2 (50 U/mL), IL-10 (10 ng/mL), CD40L (100 ng/mL), and F (ab’)2 anti-IgD antibody (1 μg/mL) for 7 days. Maturation was measured by the expression of CD27. EC50: 245 nM; n = 4. e Antibody production was measured by the concentration of IgM in supernatant samples from c. EC50: 216 nM; n = 4. Error bars represent standard error of the mean (SEM). * Indicates P < 0.05 as calculated by repeated measures one-way ANOVA

Back to article page